Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018
Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com 2
Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Introduction DelveInsight's, Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Non Alcoholic Fatty Liver Disease (NAFLD). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Non Alcoholic Fatty Liver Disease (NAFLD) Coverage of API manufacturers for Non Alcoholic Fatty Liver Disease (NAFLD) marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location. Emerging Phase III products for Non Alcoholic Fatty Liver Disease (NAFLD) This report provides a comprehensive understanding of the emerging Phase III therapies for Non Alcoholic Fatty Liver Disease (NAFLD) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020. Methodology The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases. Scope A review of the marketed products for Non Alcoholic Fatty Liver Disease (NAFLD) including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details. Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details API manufacturers for the marketed products with location details Emerging Phase III product profiles for Non Alcoholic Fatty Liver Disease (NAFLD) including product description, developmental activities, licensors & collaborators and chemical information Reasons to Buy API intelligence for marketed drugs for the indication and gaining insights of API manufacturers Evaluate the marketing status and patent details of products to exploit opportunities for generic drug 3
development Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space Additional Details Publisher : Delve Insight Reference : DIIT0058 Number of Pages : 60 Report Format : PDF Publisher Information : DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers. We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain. 4
Table Of Contents for Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018] 1. Report Introduction2. Non Alcoholic Fatty Liver Disease (NAFLD) : Overview Risk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment3. Comparative Analysis of Marketed and Emerging Products4. Marketed Therapies4.1. Drug 1: Company name Product Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities4.1.1 Product Details United States Europe4.1.2 Global Sales Assessment Historical Global Sales Forecasted Global Sales4.1.3 Patent DetailsOther marketed products in the detailed report 5. Emerging Therapies (Phase III)5.1 Drug Name : Company Name Product Description Research and Development Product Development Activities5.1.1 Forecasted Global SalesOther Phase III profiles in the detailed report AppendixMethodologyConsulting ServicesAbout DelveInsightContact Us 5
List Of Tables in Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018] Table 1: List of Marketed and Emerging Products Table 2: Drug Product Details, United States Table 3: Drug Product Details, Europe Table 4: Drug, Historical Global Sales till 2017 (in million USD) Table 5: Drug, Forecasted Global Sales from 2018-2020 (in million USD) Table 6: API Manufacturers Region wise Table 7: API Manufacturers for United States Table 8: API Manufacturers for Europe Table 9: API Manufacturers for China Table 10: API Manufacturers for India Table 11: Patent Details Table 12: Emerging Therapies (Phase III) Table 13: Drug, Forecasted Global Sales from 2018-2020 (in million USD) 6
List Of Figures, Charts and Diagrams in Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018] Figure 1: Comparative Analysis of Marketed and Emerging Products Figure 2: Drug, Historical Global Sales till 2017 (in million USD) Figure 3: Drug, Forecasted Global Sales from 2018-2020 (in million USD) Figure 4: Patent Details Figure 5: API Manufacturers Region wise Figure 6: Drug, Forecasted Global Sales from 2018-2020 (in million USD) 7
How to Buy... Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2000 Single User Price $4000 Site License Price $6000 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1300 321501 We will be delighted to give you our personal attention. 8